Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.38 |
| ▸ | MKNK1 | Q9BUB5 | 5/20 | 0.37 |
| ▸ | MKNK2 | Q9HBH9 | 5/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.36 |
| ▸ | SRC | P12931 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.35 |
| ▸ | GHSR | Q92847 | 3/20 | 0.35 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.35 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30252690 | 0.84 | CHEK2 (0.49) | CYP2A6CHEK2NTRK1 | |
| SCHEMBL30440577 | 0.81 | SRC (0.51) | MKNK1MKNK2CHEK2SRC | |
| SCHEMBL19376938 | 0.81 | MKNK1 (0.55) | CYP2A6MKNK1MKNK2CHEK2 | |
| SCHEMBL19376930 | 0.80 | CHEK2 (0.44) | HDAC1HDAC6MKNK1MKNK2CHEK2 | |
| SCHEMBL17673091 | 0.78 | PIM2 (0.44) | HDAC1 | |
| SCHEMBL29584647 | 0.78 | PIM2 (0.44) | HDAC1 | |
| SCHEMBL31207028 | 0.77 | ADRB2 (0.58) | ADRB2 | |
| SCHEMBL2714933 | 0.77 | GABRA1 (0.42) | HDAC1HDAC6MKNK1MKNK2RAB9A | |
| SCHEMBL17675624 | 0.77 | EGLN1 (0.41) | CYP2A6HDAC1MKNK1MKNK2SRC | |
| Pyridine Acetamide SCHEMBL29431271 | 0.74 | RAB9A (0.54) | RAB9ANPC1PARP10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10793560-B2 | N-pyridinyl acetamide derivatives as inhibitors of the WNT signaling pathway | REDX PHARMA PLC (GB) | 2020-10-06 | — | — | US | disclosed |
| US-20180319788-A1 | N-PYRIDINYL ACETAMIDE DERIVATIVES AS INHIBITORS OF THE WNT SIGNALING PATHWAY | REDX PHARMA PLC (GB) | 2018-11-08 | — | — | US | disclosed |
| US-20170275276-A1 | N-PYRIDINYL ACETAMIDE DERIVATIVES AS INHIBITORS OF THE WNT SIGNALING PATHWAY | REDX PHARMA PLC (GB) | 2017-09-28 | — | — | US | disclosed |
| EP-3204378-A1 | N-PYRIDINYL ACETAMIDE DERIVATIVES AS INHIBITORS OF THE WNT SIGNALLING PATHWAY | Redx Pharma PLC (GB) | 2017-08-16 | — | — | EP | disclosed |
| WO-2016055786-A1 | N-PYRIDINYL ACETAMIDE DERIVATIVES AS INHIBITORS OF THE WNT SIGNALLING PATHWAY | REDX PHARMA PLC (GB) | 2016-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10793560-B2 | N-pyridinyl acetamide derivatives as inhibitors of the WNT signaling pathway | WNT1, WNT3, CTNNB1 | ADRB2 3026/4885CYP2A6 1883/4885HDAC1 197/4885 |
| US-20180319788-A1 | N-PYRIDINYL ACETAMIDE DERIVATIVES AS INHIBITORS OF THE WNT SIGNALING PATHWAY | WNT1, WNT3, CTNNB1 | ADRB2 3026/4885CYP2A6 1883/4885HDAC1 197/4885 |
| US-20170275276-A1 | N-PYRIDINYL ACETAMIDE DERIVATIVES AS INHIBITORS OF THE WNT SIGNALING PATHWAY | WNT1, WNT3, CTNNB1 | ADRB2 3026/4885CYP2A6 1883/4885HDAC1 197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.